Anticancer vaccine contg hepatitis virus A - obtd from blood of viral hepatitis patient

摘要

Anticancer vaccine cont hepatitis virus A is produced by aseptically taking blood from a patient on the first appearance of symptoms confirming the diagnosis of visal hepatitis, as indicated by the level of transaminases in the blood and pref. just before the appearance of jaundice, centrifuging and recovering the serum. It is then tested for Australia antigen and eliminated if this or pathogenic germs are present. A marmoset is inoculated with the serum to ensure the presence of active hepatitis virus, and the tested vaccine is stored in sterile conditions at 4 degrees C.